26 LANDSDOWNE STREET, CAMBRIDGE, MA
Termination of License Agreement with Bio Palette Co., Ltd.
Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Material Contracts
Director Resignation - Carole Ho Steps Down from Beam Therapeutics Board
Investor Presentation
Bristol-Myers Squibb Completes Acquisition of Orbital Therapeutics
Reports Third Quarter 2025 Financial Results and Recent Business Updates
Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Free Writing Prospectus